Overview

* Cytek Q2 2025 revenue falls 2%, missing analyst expectations, per LSEG data

* Net loss narrows to $5.6 mln from $10.4 mln in Q2 2024

* Co launches Cytek Aurora Evo system and repurchases $4.5 mln stock in the qtr

Outlook

* Cytek narrows 2025 revenue guidance to $196 mln-$205 mln

* Company expects full-year revenue growth of -2% to +2%

Result Drivers

* REVENUE DECLINE - Lower product revenue in EMEA and APAC contributed to a 2% decline in total revenue

* RECURRING REVENUE GROWTH - Service and reagent revenues grew 16%, accounting for 32% of last 12 months' total revenue

* INSTRUMENT EXPANSION - Installed base grew by 146 units, representing 3% unit growth, despite challenging macro environment

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $45.60 $46.30

Revenue mln mln (4

Analysts

)

Q2 Net -$5.58

Income mln

Q2 $1.27

Adjusted mln

EBITDA

Q2 52.0%

Adjusted

Gross

Margin

Q2 -$6.78

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Cytek Biosciences Inc ( CTKB ) is $5.50, about 29.5% above its August 5 closing price of $3.88

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)